H.B. Fuller Company (FUL) commenced a private offering of $950 million aggregate principal amount of new senior unsecured notes due 2034, subject to market and other customary conditions. It intends to use the proceeds, together with other available cash and borrowings, to fund the Advanced Medical Solutions Group plc acquisition and related costs, repay other borrowings under its credit agreement and its 4.000% notes due February 15, 2027, and for general corporate purposes.
If the acquisition is not consummated on or before June 25, 2027 (an Outside Date that may be extended, but not beyond the first anniversary of the notes’ issue date), or H.B. Fuller notifies the trustee that the Co-operation Agreement has been terminated and the acquisition will not occur by the Outside Date, it must redeem $450 million of notes at 100% of the initial issue price plus accrued and unpaid interest. Unaudited pro forma combined-company figures for the twelve months ended August 29, 2026 include net revenue of $3,867.093 million, net income attributable to FUL or AMS, as applicable, of $100.340 million, and Adjusted EBITDA of $713.462 million; the pro forma net total leverage ratio was 4.2x. The information was not prepared in accordance with Article 11 of Regulation S-X.
Fuller H B Co. (FUL) director R. Jeffrey Bailly received an award of 1,300 restricted stock units on September 30, 2026, bringing his reported direct RSU holdings to 1,300. The units convert into common stock on a 1-for-1 basis.
H.B. Fuller Co. director Michael J. Happe purchased 2,000 common shares on September 29, 2026, at $49.625 per share. He reported 3,343 common shares held directly afterward; no Rule 10b5-1 plan is reported for the purchase. He also reported 18,329.43 stock units, including units acquired through a dividend equivalent feature of the Directors' Deferred Compensation Plan.
FUL director Celine Christine Martin purchased 464.599 common shares on September 30, 2026, at a weighted average price of $49.50 per share; the footnote lists 464 shares at $49.50 and 0.599 share at $49.51. Her direct common-stock position after the purchase was 464.599 shares. She also reported 1,310.03 restricted stock units that convert into common stock 1-for-1 and 2,906.53 stock units that convert 1-for-1 upon retirement, death, disability or certain specified events, subject to holding periods required by law. No Rule 10b5-1 plan is reported.
Thomas W. Handley, a director of Fuller H B Co (FUL), reported a purchase through a revocable trust of 2,000 common shares at $49.41 per share on September 28, 2026; the reported position through the trust afterward was 2,000 shares. No Rule 10b5-1 plan is reported. He also reported direct holdings of 1,347 common shares and 82,171.34 Stock Units. The units convert into common stock on a 1-for-1 basis.
FUL director Daniel L. Florness reported purchasing 2,030 common shares at $49.34 per share on September 28, 2026. The shares were held in a joint account with his spouse; his reported direct common-stock balance after the purchase was 3,381 shares. No Rule 10b5-1 plan is reported for the purchase. His reported position also included 33,616.06 stock units, which convert into common stock one-for-one upon retirement, death, disability or certain plan-defined events, subject to holding periods required by law.
Fuller H B Co. (FUL) director Trangsrud Teresa J. Rasmussen reported two common-stock purchases through a revocable trust on September 28, 2026: 1,542 shares at $48.9587 per share and 500 shares at $48.98 per share. The reported positions also include 1,392 directly held common shares and 26,122.92 direct stock units. No Rule 10b5-1 plan is reported.
FUL director Charles T. Lauber purchased 2,005 common shares on September 29, 2026, at a weighted average price of $49.8676 per share; reported prices ranged from $49.7767 to $49.9400. His directly held common-share position after the purchase was 3,356 shares. He also reported 13,169.880 directly held stock units, convertible into common shares 1-for-1 upon retirement, death, disability or certain specified plan events, subject to holding periods required by law. No Rule 10b5-1 plan is reported.
Fuller H B Co. (FUL) director Srilata Zaheer directly purchased 2,000 common shares at $49.0600 per share on September 28, 2026, and 40 common shares at $49.9726 per share on September 29, 2026. No Rule 10b5-1 plan is reported. As of September 28, 2026, she also reported 12,165 directly held Stock Units, convertible into common stock 1-for-1 upon retirement, death, disability or certain specified events, subject to holding periods required by law. The units include acquisitions under a dividend equivalent feature of the Directors' Deferred Compensation Plan.
R. Jeffrey Bailly, a director of Fuller H B Co (FUL), reports no securities beneficially owned.